Phase I study of epidermal growth factor receptor (EGFR) inhibitor, erlotinib, and vascular endothelial growth factor monoclonal antibody, bevacizumab, in recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN)

2004 ◽  
Vol 22 (14_suppl) ◽  
pp. 5539-5539 ◽  
Author(s):  
A. M. Mauer ◽  
E. E. W. Cohen ◽  
S. J. Wong ◽  
M. Kozloff ◽  
J. Winegarden ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Phase I Study ◽  
Growth Factor Receptor ◽  
Vascular Endothelial ◽  
Egfr Inhibitor ◽  
Metastatic Squamous Cell Carcinoma ◽  
Epidermal Growth ◽  
Endothelial Growth Factor

Fortgeschrittenes medulläres Schilddrüsenkarzinom: Vandetanib verbessert das progressionsfreie Überleben

2012 ◽  
Vol 03 (02) ◽  
pp. 93-92
Author(s):  
Alexander Kretzschmar
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Epidermal Growth Factor Receptor ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Growth Factor Receptor ◽  
Phase Iii ◽  
Vascular Endothelial ◽  
Medulläres Schilddrüsenkarzinom ◽  
Epidermal Growth ◽  
Endothelial Growth Factor

Vandetanib ist ein oraler Hemmer des RET-Kinase-, VEGF (Vascular Endothelial Growth Factor Receptor)- und EGFR (Epidermal Growth Factor Receptor)-Signalwegs. In einer zulassungsrelevanten, randomisierten, doppelblinden, placebokontrollierten Phase- III-Studie verlängerte der Tyrosinkinasehemmer das progressionsfreie Überleben (PFS) signifikant länger als Placebo.

Sign in / Sign up

Export Citation Format

Share Document